+ Filter
Loading...
Staphylococcus enterotoxin A
Anti-Staphylococcus enterotoxin A Recombinant Antibody Products
CompareCan't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
SEA is a member of the staphylococcal enterotoxin family, and a product of staphylococcus aureus.
The SEA can effectively activate the body's immune system, which mainly produce large amounts of CTLs and a series of cytokines, have cytotoxic effects on MHC-2 positive cells (staphylococcalenterotoxin-dependent cell-mediated cytotoxitySDCC).
Staphylococcal enterotoxin A (SEA) belongs to A family of superantigens. Many in vivo and in vitro experiments have proved that it has A strong anti-tumor immune effect. However, SEA has great toxic and side effects on the organism, and reducing its distribution in non-tumor regions is an effective way to reduce its side effects. Liposome, as an anti-tumor drug carrier, has made great progress. Its outstanding feature is that it can change the distribution of drugs in the body, that is, liposome with a certain particle size is mainly consumed by reticuloendothelial cell system and distributed in the liver and spleen. We prepared SEA liposomes to make SEA mainly concentrate in liver, so as to reduce the toxic and side effects of SEA and explore a new approach for the treatment of liver cancer.
The SEA can effectively activate the body's immune system, which mainly produce large amounts of CTLs and a series of cytokines, have cytotoxic effects on MHC-2 positive cells (staphylococcalenterotoxin-dependent cell-mediated cytotoxitySDCC).
Staphylococcal enterotoxin A (SEA) belongs to A family of superantigens. Many in vivo and in vitro experiments have proved that it has A strong anti-tumor immune effect. However, SEA has great toxic and side effects on the organism, and reducing its distribution in non-tumor regions is an effective way to reduce its side effects. Liposome, as an anti-tumor drug carrier, has made great progress. Its outstanding feature is that it can change the distribution of drugs in the body, that is, liposome with a certain particle size is mainly consumed by reticuloendothelial cell system and distributed in the liver and spleen. We prepared SEA liposomes to make SEA mainly concentrate in liver, so as to reduce the toxic and side effects of SEA and explore a new approach for the treatment of liver cancer.
